NO952884L - Spirocykloalkyl-substituerte azetidinoner som er anvendbare som hypokolesterolemiske midler - Google Patents
Spirocykloalkyl-substituerte azetidinoner som er anvendbare som hypokolesterolemiske midlerInfo
- Publication number
- NO952884L NO952884L NO952884A NO952884A NO952884L NO 952884 L NO952884 L NO 952884L NO 952884 A NO952884 A NO 952884A NO 952884 A NO952884 A NO 952884A NO 952884 L NO952884 L NO 952884L
- Authority
- NO
- Norway
- Prior art keywords
- optionally substituted
- lower alkyl
- alkenylene
- sum
- compounds
- Prior art date
Links
- 239000003529 anticholesteremic agent Substances 0.000 title abstract 2
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000004450 alkenylene group Chemical group 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 abstract 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/12—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US643993A | 1993-01-21 | 1993-01-21 | |
| PCT/US1994/000421 WO1994017038A1 (en) | 1993-01-21 | 1994-01-19 | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO952884D0 NO952884D0 (no) | 1995-07-20 |
| NO952884L true NO952884L (no) | 1995-09-20 |
Family
ID=21720894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO952884A NO952884L (no) | 1993-01-21 | 1995-07-20 | Spirocykloalkyl-substituerte azetidinoner som er anvendbare som hypokolesterolemiske midler |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US5698548A (lt) |
| EP (1) | EP0681569B1 (lt) |
| JP (1) | JP2719445B2 (lt) |
| KR (1) | KR960700227A (lt) |
| CN (1) | CN1118163A (lt) |
| AT (1) | ATE199899T1 (lt) |
| AU (1) | AU683048B2 (lt) |
| CA (1) | CA2154257C (lt) |
| CZ (1) | CZ180195A3 (lt) |
| DE (1) | DE69426924T2 (lt) |
| DK (1) | DK0681569T3 (lt) |
| EE (1) | EE9400394A (lt) |
| ES (1) | ES2155849T3 (lt) |
| FI (1) | FI953497A0 (lt) |
| GR (1) | GR3035963T3 (lt) |
| HU (1) | HUT72592A (lt) |
| IL (1) | IL108368A0 (lt) |
| LT (1) | LT3595B (lt) |
| NO (1) | NO952884L (lt) |
| NZ (1) | NZ261714A (lt) |
| PL (1) | PL309978A1 (lt) |
| PT (1) | PT681569E (lt) |
| SI (1) | SI9400022A (lt) |
| SK (1) | SK91195A3 (lt) |
| WO (1) | WO1994017038A1 (lt) |
| ZA (1) | ZA94386B (lt) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ331094A3 (en) * | 1992-06-26 | 1995-09-13 | Pfizer | Steroidal glycosides and their use for treating hypercholesterolemia and atherosclerosis |
| US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5656624A (en) * | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
| US5648484A (en) * | 1995-03-07 | 1997-07-15 | Schering Corporation | Catalytic enantioselective synthesis of a spriofused azetidinone |
| DE69621952T2 (de) | 1995-10-31 | 2003-01-16 | Schering Corp., Kenilworth | Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel |
| US5756470A (en) * | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| AR023463A1 (es) | 1999-04-16 | 2002-09-04 | Schering Corp | Uso de compuestos de azetidinona |
| US6297268B1 (en) | 1999-11-30 | 2001-10-02 | Schering Corporation | Imidazoles as cholesterol lowering agents |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| DE60106489T2 (de) * | 2000-12-20 | 2005-10-13 | Schering Corp. | Zuckersubstituierte 2-azetidinone verwendbar als hypocholesterdenische arzneimittel |
| IL156488A0 (en) * | 2001-01-26 | 2004-01-04 | Schering Corp | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions |
| EP1911462A3 (en) | 2001-01-26 | 2011-11-30 | Schering Corporation | Compositions comprising a sterol absorption inhibitor |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| PT1355644E (pt) * | 2001-01-26 | 2006-11-30 | Schering Corp | Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia |
| AU2005246926B2 (en) * | 2001-01-26 | 2008-02-28 | Merck Sharp & Dohme Corp. | The use of substituted azetidinone compounds for the treatment of sitosterolemia |
| RS20100015A (sr) | 2001-01-26 | 2010-12-31 | Schering Corporation | Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije |
| IL157552A0 (en) | 2001-03-28 | 2004-03-28 | Schering Corp | Enantioselective synthesis of azetidinone intermediate compounds |
| SI1429756T1 (sl) * | 2001-09-21 | 2007-02-28 | Schering Corp | Zdravljenje ksantomov z azetidinonskimi derivati kot inhibitorji absorpcije sterola |
| EP1429756B1 (en) | 2001-09-21 | 2006-11-22 | Schering Corporation | Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| US20030204096A1 (en) * | 2002-03-25 | 2003-10-30 | Schering Corporation | Enantioselective synthesis of azetidinone intermediate compounds |
| GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
| US20040132058A1 (en) | 2002-07-19 | 2004-07-08 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
| US7135556B2 (en) * | 2002-07-19 | 2006-11-14 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
| AR040588A1 (es) | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
| ATE485818T1 (de) * | 2002-07-30 | 2010-11-15 | Karykion Inc | Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren |
| JP2006508188A (ja) | 2002-11-06 | 2006-03-09 | シェーリング コーポレイション | 脱髄の処置のためのコレステロール吸収インヒビター |
| DE602004016123D1 (de) | 2003-03-07 | 2008-10-09 | Schering Corp | Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia |
| CN1756756A (zh) | 2003-03-07 | 2006-04-05 | 先灵公司 | 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
| CN1756755A (zh) | 2003-03-07 | 2006-04-05 | 先灵公司 | 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| AU2004233863B2 (en) | 2003-04-24 | 2010-06-17 | Incyte Holdings Corporation | Aza spiro alkane derivatives as inhibitors of metalloproteases |
| JP2005015434A (ja) * | 2003-06-27 | 2005-01-20 | Kotobuki Seiyaku Kk | 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤 |
| EP1918000A2 (en) | 2003-11-05 | 2008-05-07 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
| JP2007510659A (ja) * | 2003-11-05 | 2007-04-26 | シェーリング コーポレイション | 脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置 |
| CA2550215A1 (en) | 2003-12-23 | 2005-07-07 | Astrazeneca Ab | Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity |
| WO2005062824A2 (en) * | 2003-12-23 | 2005-07-14 | Merck & Co., Inc. | Anti-hypercholesterolemic compounds |
| WO2005069900A2 (en) * | 2004-01-16 | 2005-08-04 | Merck & Co., Inc. | Npc1l1 (npc3) and methods of identifying ligands thereof |
| US20080045726A1 (en) * | 2004-05-10 | 2008-02-21 | Laboratorios Del Dr. Esteve, S.A. | Spirolactams and Their Synthesis |
| EP1747197A1 (en) * | 2004-05-10 | 2007-01-31 | Laboratorios Del Dr. Esteve, S.A. | Regioselective functionalisation and protection of spirolactams |
| EP1598336A1 (en) * | 2004-05-20 | 2005-11-23 | Laboratorios Del Dr. Esteve, S.A. | Regioselective hydroxylation, functionalisation and protection of spirolactams |
| US7291728B2 (en) | 2004-05-10 | 2007-11-06 | Laboratories Del Dr. Esteve, S.A. | Spirolactams and their synthesis |
| EP1676836A1 (en) * | 2004-12-30 | 2006-07-05 | Laboratorios Del Dr. Esteve, S.A. | Regioselective hydroxylation, functionalisation and protection of spirolactams II |
| JP2008514718A (ja) * | 2004-09-29 | 2008-05-08 | シェーリング コーポレイション | 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ |
| WO2006060461A1 (en) | 2004-12-03 | 2006-06-08 | Schering Corporation | Substituted piperazines as cb1 antagonists |
| US8361999B2 (en) | 2005-04-04 | 2013-01-29 | Pontificia Universidad Catolica De Chile | Methods of treating cholesterol gallstone disease with ezetimibe |
| JP2008546784A (ja) * | 2005-06-20 | 2008-12-25 | シェーリング コーポレイション | ヒスタミンｈ３アンタゴニストとして有用なピペリジン誘導体 |
| SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
| CA2634940A1 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist |
| BRPI0706623A2 (pt) | 2006-01-18 | 2011-04-12 | Schering Corp | moduladores de receptor canabinóide |
| EP1986489A2 (en) * | 2006-02-24 | 2008-11-05 | Schering Corporation | Npc1l1 orthologues |
| AR060623A1 (es) | 2006-04-27 | 2008-07-02 | Astrazeneca Ab | Compuestos derivados de 2-azetidinona y un metodo de preparacion |
| US20080103122A1 (en) * | 2006-09-05 | 2008-05-01 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
| JP2010503676A (ja) * | 2006-09-15 | 2010-02-04 | シェーリング コーポレイション | 疼痛、糖尿病および脂質代謝の障害の治療 |
| CA2663500A1 (en) | 2006-09-15 | 2008-03-20 | Schering Corporation | Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism |
| CA2663503A1 (en) * | 2006-09-15 | 2008-03-20 | Schering Corporation | Azetidinone derivatives and methods of use thereof |
| CN101541805A (zh) * | 2006-09-15 | 2009-09-23 | 先灵公司 | 用于治疗疼痛和脂代射紊乱的氮杂环丁烷和氮杂环丁酮衍生物 |
| JP2010503673A (ja) * | 2006-09-15 | 2010-02-04 | シェーリング コーポレイション | 疼痛および脂質代謝障害を処置する際に有用なアゼチジン誘導体およびアゼチドン誘導体 |
| US20080070890A1 (en) * | 2006-09-15 | 2008-03-20 | Burnett Duane A | Spirocyclic Azetidinone Compounds and Methods of Use Thereof |
| MX2009002921A (es) | 2006-09-15 | 2009-04-01 | Schering Corp | Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico. |
| US20100197564A1 (en) * | 2007-04-19 | 2010-08-05 | Schering Corporation | Diaryl morpholines as cb1 modulators |
| EP2548874A3 (en) | 2007-06-28 | 2013-05-15 | Intervet International B.V. | Substituted piperazines as CB1 antagonists |
| US20100286160A1 (en) * | 2007-06-28 | 2010-11-11 | Intervet Inc. | Substituted piperazines as cb1 antagonists |
| WO2010100255A1 (en) | 2009-03-06 | 2010-09-10 | Lipideon Biotechnology Ag | Pharmaceutical hypocholesterolemic compositions |
| CN101993403B (zh) * | 2009-08-11 | 2012-07-11 | 浙江海正药业股份有限公司 | 氮杂环丁酮类化合物及医药应用 |
| PL2547679T3 (pl) | 2010-03-19 | 2016-02-29 | Pfizer | Pochodne 2,3-dihydro-1H-inden-1-ylo-2,7-diazaspiro[3.5]nonanu i ich zastosowanie jako antagonistów lub odwrotnych agonistów receptora greliny |
| EP2844233B1 (en) | 2012-05-01 | 2020-05-06 | Althera Life Sciences, LLC | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases |
| CN104496839B (zh) * | 2014-12-03 | 2016-04-20 | 广东东阳光药业有限公司 | 取代环丁烷类神经氨酸酶抑制剂及其使用方法和用途 |
| CN104496838B (zh) * | 2014-12-03 | 2016-04-20 | 广东东阳光药业有限公司 | 取代环丁烷类神经氨酸酶抑制剂及其使用方法和用途 |
| WO2020104930A1 (en) | 2018-11-20 | 2020-05-28 | Piramal Enterprises Limited | An improved asymmetric synthesis of azaspiro compounds |
| JP7574206B2 (ja) | 2019-03-20 | 2024-10-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ステロール調節エレメント結合転写因子１（ｓｒｅｂｆ１）阻害剤による上昇した脂質レベルの治療 |
| WO2020191163A1 (en) | 2019-03-20 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (scap) inhibitors |
| AU2022421224A1 (en) * | 2021-12-22 | 2024-06-20 | The Regents Of The University Of California | Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase |
| WO2025049558A1 (en) | 2023-08-29 | 2025-03-06 | Regeneron Pharmaceuticals, Inc. | Treatment of liver disease or metabolic disorder with folliculin interacting protein 1 (fnip1) inhibitors and/or folliculin (flcn) inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2048080C3 (de) * | 1970-09-30 | 1979-11-29 | Basf Ag, 6700 Ludwigshafen | Verfahren zur Herstellung von N-substituierten 33-disubstituierten ß -Lactamen |
| US4692515A (en) * | 1984-09-24 | 1987-09-08 | Pennwalt Corporation | Adamantane-spirolactams |
| IL89835A0 (en) | 1988-04-11 | 1989-12-15 | Merck & Co Inc | Substituted azetidinones,their preparation and pharmaceutical compositions containing them |
| US4983597A (en) | 1989-08-31 | 1991-01-08 | Merck & Co., Inc. | Beta-lactams as anticholesterolemic agents |
| US5130425A (en) * | 1990-10-12 | 1992-07-14 | American Home Products Corporation | Spiro-lactams and analogs thereof useful as aldose reductase inhibitors |
| TW223059B (lt) * | 1991-07-23 | 1994-05-01 | Schering Corp |
-
1994
- 1994-01-13 LT LTIP1764A patent/LT3595B/lt not_active IP Right Cessation
- 1994-01-19 PT PT94907200T patent/PT681569E/pt unknown
- 1994-01-19 DK DK94907200T patent/DK0681569T3/da active
- 1994-01-19 FI FI953497A patent/FI953497A0/fi not_active Application Discontinuation
- 1994-01-19 JP JP6517083A patent/JP2719445B2/ja not_active Expired - Fee Related
- 1994-01-19 CN CN94191245A patent/CN1118163A/zh active Pending
- 1994-01-19 CZ CZ951801A patent/CZ180195A3/cs unknown
- 1994-01-19 ES ES94907200T patent/ES2155849T3/es not_active Expired - Lifetime
- 1994-01-19 EP EP94907200A patent/EP0681569B1/en not_active Expired - Lifetime
- 1994-01-19 PL PL94309978A patent/PL309978A1/xx unknown
- 1994-01-19 SK SK911-95A patent/SK91195A3/sk unknown
- 1994-01-19 AU AU60872/94A patent/AU683048B2/en not_active Expired - Fee Related
- 1994-01-19 DE DE69426924T patent/DE69426924T2/de not_active Expired - Lifetime
- 1994-01-19 NZ NZ261714A patent/NZ261714A/en unknown
- 1994-01-19 CA CA002154257A patent/CA2154257C/en not_active Expired - Fee Related
- 1994-01-19 SI SI9400022A patent/SI9400022A/sl unknown
- 1994-01-19 IL IL10836894A patent/IL108368A0/xx unknown
- 1994-01-19 AT AT94907200T patent/ATE199899T1/de not_active IP Right Cessation
- 1994-01-19 HU HU9502194A patent/HUT72592A/hu unknown
- 1994-01-19 ZA ZA94386A patent/ZA94386B/xx unknown
- 1994-01-19 WO PCT/US1994/000421 patent/WO1994017038A1/en not_active Ceased
- 1994-11-23 EE EE9400394A patent/EE9400394A/xx unknown
-
1995
- 1995-05-25 US US08/449,980 patent/US5698548A/en not_active Expired - Lifetime
- 1995-07-20 NO NO952884A patent/NO952884L/no unknown
- 1995-07-21 KR KR1019950702988A patent/KR960700227A/ko not_active Abandoned
-
2001
- 2001-05-31 GR GR20010400814T patent/GR3035963T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE69426924T2 (de) | 2001-08-16 |
| DK0681569T3 (da) | 2001-04-23 |
| HU9502194D0 (en) | 1995-09-28 |
| ZA94386B (en) | 1994-07-19 |
| IL108368A0 (en) | 1994-04-12 |
| LT3595B (en) | 1995-12-27 |
| AU683048B2 (en) | 1997-10-30 |
| EE9400394A (et) | 1996-06-17 |
| PT681569E (pt) | 2001-06-29 |
| US5698548A (en) | 1997-12-16 |
| CZ180195A3 (en) | 1996-01-17 |
| ES2155849T3 (es) | 2001-06-01 |
| PL309978A1 (en) | 1995-11-13 |
| GR3035963T3 (en) | 2001-08-31 |
| SK91195A3 (en) | 1995-12-06 |
| NZ261714A (en) | 1997-02-24 |
| KR960700227A (ko) | 1996-01-19 |
| DE69426924D1 (de) | 2001-04-26 |
| SI9400022A (en) | 1995-02-28 |
| CA2154257A1 (en) | 1994-08-04 |
| EP0681569B1 (en) | 2001-03-21 |
| ATE199899T1 (de) | 2001-04-15 |
| HUT72592A (en) | 1996-05-28 |
| CA2154257C (en) | 1999-05-25 |
| FI953497A7 (fi) | 1995-07-20 |
| CN1118163A (zh) | 1996-03-06 |
| JP2719445B2 (ja) | 1998-02-25 |
| JPH08501110A (ja) | 1996-02-06 |
| NO952884D0 (no) | 1995-07-20 |
| LTIP1764A (en) | 1995-02-27 |
| WO1994017038A1 (en) | 1994-08-04 |
| AU6087294A (en) | 1994-08-15 |
| EP0681569A1 (en) | 1995-11-15 |
| FI953497A0 (fi) | 1995-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2154257A1 (en) | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents | |
| CA2152351C (en) | Combination of a cholesterol biosynthesis inhibitor and a .beta.-lactam cholesterol absorption inhibitor | |
| IE892081L (en) | Cholesterol-Lowering Combination Compositions of Guar Gum¹and Niacin | |
| MY130157A (en) | Method of use for inhibiting bone loss and lowering serum cholesterol | |
| NO975632D0 (no) | Dinukleotider som er nyttige for behandling av lungesykdom | |
| BRPI0015947A (pt) | derivado de 6-mercapto-ciclodextrina, uso do mesmo, kit para fornecer bloqueio neuromuscular e sua reversão, composição farmacêutica, e, método para a reversão do bloqueio neuromuscular induzido por medicamento em um paciente. | |
| KR920011471A (ko) | 구강용 치석방지 조성물, 치약 및 치석 방지 방법 | |
| KR880006229A (ko) | 항궤양 활성을 갖는 피리딘 유도체 | |
| NO944919L (no) | Fremgangsmåte for å inhibere atrofi av huden eller vagina | |
| CA2248032A1 (en) | Serum cholesterol lowering agent | |
| RU94013440A (ru) | Производные 3-дезоксиолисахаридов, способы их получения и содержащие их фармацевтические композиции | |
| CLARKE-PEARSON et al. | Complications of low-dose heparin prophylaxis in gynecologic oncology surgery | |
| DE69033183D1 (de) | Phosphozucker enthaltende pharmazeutische zubereitung | |
| TW354762B (en) | Agent for prophylaxis or treatment of cataract | |
| Toomes et al. | Decortication of the lung | |
| EP0990439A4 (en) | BISARYL COMPOUNDS AND ANTICIPATING MEDICAMENTS CONTAINING THEM | |
| Herbai | TREATMENT OF PROGRESSIVE SYSTEMIC SCLEROSIS WITH A SYNTHETIC WEAK ESTROGEN: CYCLOFENIL (SEXOVID®) Report of a Case | |
| WO1984004453A1 (en) | Oral dental care composition | |
| JP2004522711A5 (lt) | ||
| DK0912568T3 (da) | Imidazopyridiner | |
| JPH05504971A (ja) | バムブテロールを含む脂質低下用医薬組成物 | |
| EP0304842A3 (en) | Isoprenoid derivatives and anti-ulcer agents containing the same | |
| EE9800134A (et) | Farmatseutiline kompositsioon intravenoosseks manustamiseks | |
| AU565187B2 (en) | 2-n-cycloalkylmethyl-3-oxo-5,6-diaryl-as-triazines | |
| Furnival et al. | IN‐VITRO STUDIES OF GALLSTONE DISSOLUTION: THE EFFECT OF ADDED HEPARIN IN BILE SALT SOLUTIONS |